Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DIPY14
|
|||
| Drug Name |
NOV1501
|
|||
| Synonyms |
ABL001; TR009
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
ABL Bio
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Delta-like protein 4 (DLL4) | Target Info | Inhibitor | [2] |
| Vascular endothelial growth factor (VEGF) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Notch signaling pathway | |||
| NetPath Pathway | Notch Signaling Pathway | |||
| Panther Pathway | Angiogenesis | |||
| Notch signaling pathway | ||||
| Pathway Interaction Database | Notch signaling pathway | |||
| Reactome | Activated NOTCH1 Transmits Signal to the Nucleus | |||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | ||||
| Constitutive Signaling by NOTCH1 t(7 | ||||
| M1580_K2555) Translocation Mutant | ||||
| Constitutive Signaling by NOTCH1 HD Domain Mutants | ||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | ||||
| NOTCH2 Activation and Transmission of Signal to the Nucleus | ||||
| WikiPathways | Notch Signaling Pathway | |||
| Signaling by NOTCH3 | ||||
| Signaling by NOTCH4 | ||||
| Signaling by NOTCH1 | ||||
| Signaling by NOTCH2 | ||||
| Notch Signaling Pathway | ||||
| Neural Crest Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03292783) This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001. U.S. National Institutes of Health. | |||
| REF 2 | Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.